English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Agenix to File for Clinical Trials of Hepatitis Treatment in China

Mar. 29, 2012

Together with its strategic partner in China, the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Sciences, the Melbourne-based company Agenix will submit an SFDA application to begin clinical trials of its lead drug AGX-1009, a treatment for hepatitis B, in China. Subject to approval of the application by the SFDA, the trials would be able to commence in 2013.